Similar articles

• Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components.

  Jick H, Jick SS, Gurewich V, Myers MW, Vasilakis C. Jick H, et al. Lancet. 1995 Dec 16;346(8990):1589-93. doi: 10.1016/s0140-6736(95)91928-7. Lancet. 1995. PMID: 7500750
• Venous thromboembolism and desogestrel- or gestodene-containing combination oral contraceptives: what are the facts?

  [No authors listed] [No authors listed] Contracept Rep. 1996 Apr;7(1):3-6. Contracept Rep. 1996. PMID: 12320047
• Modern oral contraceptives and cardiovascular disease.

  Rosenberg L, Palmer JR, Sands MI, Grimes D, Bergman U, Daling J, Mills A. Rosenberg L, et al. Am J Obstet Gynecol. 1997 Sep;177(3):707-15. doi: 10.1016/s0002-9378(97)70168-6. Am J Obstet Gynecol. 1997. PMID: 9322646 Review.
• Newer oral contraceptives and the risk of venous thromboembolism.

  Walker AM. Walker AM. Contraception. 1998 Mar;57(3):169-81. doi: 10.1016/s0010-7824(98)00014-6. Contraception. 1998. PMID: 9617533 Review.
• Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic disease. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception.

  [No authors listed] [No authors listed] Lancet. 1995 Dec 16;346(8990):1582-8. Lancet. 1995. PMID: 7500749